title: Tyrosine-kinases inhibitors in recurrent platinum-resistant ovarian cancer patients.
abstract: For many decades, ovarian cancer (OC) has been one of the most common gynecological cancer. Despite advances in OC diagnosis and treatment, the risk of recurrence is ever present and approximately 85% of patients will experience relapse. Recurrent OC after first-line therapy is almost always incurable. Multiple novel therapies, including tyrosine-kinases inhibitors (TKI), have shown promising results, but their role needs to be clarified. In this review we describe the rationale and the clinical evidence regarding the use of TKI for the treatment of recurrent platinum-resistant OC patients.
authors.affiliation: Department of Gynecological and Obstetrical Sciences and Urological Sciences, "Sapienza" University of Rome, Rome, Italy. Electronic address: clamarchetti@libero.it.
authors.forename: C
authors.initials: C
authors.lastname: Marchetti
authors.affiliation: Department of Gynecological and Obstetrical Sciences and Urological Sciences, "Sapienza" University of Rome, Rome, Italy. Electronic address: innocenza.palai@uniroma1.it.
authors.forename: I
authors.initials: I
authors.lastname: Palaia
authors.affiliation: Department of Radiotherapy, Policlinico Umberto I, "Sapienza" University of Rome, Rome, Italy. Electronic address: fradefelice@hotmail.it.
authors.forename: F
authors.initials: F
authors.lastname: De Felice
authors.affiliation: Department of Gynecological and Obstetrical Sciences and Urological Sciences, "Sapienza" University of Rome, Rome, Italy. Electronic address: angela.musell@gmail.com.
authors.forename: A
authors.initials: A
authors.lastname: Musella
authors.affiliation: Department of Gynecological and Obstetrical Sciences and Urological Sciences, "Sapienza" University of Rome, Rome, Italy. Electronic address: cristina.donfancesco@uniroma1.it.
authors.forename: C
authors.initials: C
authors.lastname: Donfracesco
authors.affiliation: Department of Gynecological and Obstetrical Sciences and Urological Sciences, "Sapienza" University of Rome, Rome, Italy. Electronic address: lauravertecy@uniroma1.it.
authors.forename: L
authors.initials: L
authors.lastname: Vertechy
authors.affiliation: Department of Gynecological and Obstetrical Sciences and Urological Sciences, "Sapienza" University of Rome, Rome, Italy. Electronic address: alessia.romto@uniroma1.it.
authors.forename: A
authors.initials: A
authors.lastname: Romito
authors.affiliation: Department of Gynecological and Obstetrical Sciences and Urological Sciences, "Sapienza" University of Rome, Rome, Italy. Electronic address: ilarapiacenti@uniroma1.it.
authors.forename: I
authors.initials: I
authors.lastname: Piacenti
authors.affiliation: Department of Radiotherapy, Policlinico Umberto I, "Sapienza" University of Rome, Rome, Italy. Electronic address: danela.musio@uniroma1.it.
authors.forename: D
authors.initials: D
authors.lastname: Musio
authors.affiliation: Department of Gynecological and Obstetrical Sciences and Urological Sciences, "Sapienza" University of Rome, Rome, Italy. Electronic address: ludovic.muzi@uniroma1.it.
authors.forename: L
authors.initials: L
authors.lastname: Muzii
authors.affiliation: Department of Radiotherapy, Policlinico Umberto I, "Sapienza" University of Rome, Rome, Italy. Electronic address: vincenzo.tombolni@uniroma1.it.
authors.forename: V
authors.initials: V
authors.lastname: Tombolini
authors.affiliation: Department of Gynecological and Obstetrical Sciences and Urological Sciences, "Sapienza" University of Rome, Rome, Italy. Electronic address: pierluigi.benedettpanici@uniroma1.it.
authors.forename: P
authors.initials: P
authors.lastname: Benedetti Panici
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy* / Q000201:enzymology / Q000556:secondary; D017322:Clinical Trials, Phase II as Topic; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D005260:Female; D006801:Humans; D058990:Molecular Targeted Therapy; D015337:Multicenter Studies as Topic; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors*; D009944:Organoplatinum Compounds / Q000494:pharmacology* / Q000627:therapeutic use; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D010534:Peritoneal Neoplasms / Q000188:drug therapy / Q000556:secondary; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012008:Recurrence; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D009363:Neoplasm Proteins; D009944:Organoplatinum Compounds; D047428:Protein Kinase Inhibitors
keywords: Gynecologic; Ovarian cancer; Platinum resistant; Recurrence; Tyrosine-kinases inhibitors